<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04815161</url>
  </required_header>
  <id_info>
    <org_study_id>171965</org_study_id>
    <nct_id>NCT04815161</nct_id>
  </id_info>
  <brief_title>ASsessment of Adherence TO Medication in AtRIAl Fibrillation - an eMonitoring Drug Dispensing Device Study</brief_title>
  <acronym>ASTORIA</acronym>
  <official_title>ASsessment of Adherence TO Medication in AtRIAl Fibrillation - an eMonitoring Drug Dispensing Device Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pilloxa</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ASTORIA study is a prospective cohort single-armed multicenter observational study that&#xD;
      aims to assess adherence to rivaroxaban using a high technological electronical pillbox&#xD;
      connected to a phone application in a group of atrial fibrillation patients with indication&#xD;
      of long term anticoagulation treatment in routine clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of adherence</measure>
    <time_frame>2 years</time_frame>
    <description>The rate of adherence to rivaroxaban in a group of atrial fibrillation patients using the Pilloxa box will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Persistence rate</measure>
    <time_frame>2 years</time_frame>
    <description>Rate of persistence to rivaroxaban in a group of atrial fibrillation patients using the Pilloxa box will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of risk factors</measure>
    <time_frame>2 years</time_frame>
    <description>Risk factors for non-adherence and non-persistence in these patients will be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of different patient experiences</measure>
    <time_frame>2 years</time_frame>
    <description>Patient experiences with the Pilloxa box and application will be evaluated using questionnaires and quality intervjues</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Adherence, Patient</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Pilloxa pillbox</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients receiving the Pilloxa pillbox for drug administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Adherence</intervention_name>
    <description>Adherence to medication using an electronic pillbox</description>
    <arm_group_label>Pilloxa pillbox</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female or male patient with age &gt; 18 years&#xD;
&#xD;
          -  Patients with atrial fibrillation&#xD;
&#xD;
          -  Patients initiated, continued on or switched to rivaroxaban for the indication atrial&#xD;
             fibrillation with intended lifelong treatment (CHA2 DS2-VASc score â‰¥ 1).&#xD;
&#xD;
          -  The patient must agree to the use of the electronic medication adherence monitoring&#xD;
             device, the so-called Pilloxa box and need to have a sufficient understanding of the&#xD;
             app and functionality in conjunction with the use of the Pilloxa box.&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  No participation in an investigational program with interventions outside of routine&#xD;
             clinical practice&#xD;
&#xD;
          -  No contra-indications according to the local marketing authorization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in an investigational program with interventions outside of routine&#xD;
             clinical practice&#xD;
&#xD;
          -  Contra-indications according to the local marketing authorization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Atar, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univerity of Oslo, Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dan Atar, MD, PhD</last_name>
    <phone>+47 22119100</phone>
    <email>dan.atar@medisin.uio.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marita Knudsen Pope, MD</last_name>
    <phone>+47 92482991</phone>
    <email>marita.knudsen.pope@gmail.com</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Dan Atar</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We do not plan to share IPD.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

